Cipla Ltd (CIPL.NS)
408.50INR
24 May 2013
Rs-6.35 (-1.53%)
Rs414.85
Rs417.00
Rs418.00
Rs406.10
1,107,334
1,228,026
Rs435.00
Rs300.00
CIPL.NS
About
Overall
| Beta: | 0.39 |
| Market Cap (Mil.): | Rs327,993.41 |
| Shares Outstanding (Mil.): | 802.92 |
| Dividend: | 2.00 |
| Yield (%): | 0.49 |
Financials
| CIPL.NS | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 33.15 | 34.04 | 34.29 |
| EPS (TTM): | 12.32 | -- | -- |
| ROI: | 14.28 | 19.04 | 18.43 |
| ROE: | 15.74 | 19.78 | 19.30 |
Cipla Medpro shareholders back buyout by India's Cipla
JOHANNESBURG - Shareholders of South Africa's Cipla Medpro overwhelmingly approved a $488 million takeover offer from India's Cipla Ltd on Wednesday, giving the Indian drugmaker a big presence in Africa's biggest economy.
Cipla Medpro shareholders back buyout by India's Cipla
JOHANNESBURG - Shareholders of South Africa's Cipla Medpro overwhelmingly approved a $488 million takeover offer from India's Cipla Ltd on Wednesday, giving the Indian drugmaker a big presence in Africa's biggest economy.
Cipla Medpro shareholders approve buyout by India's Cipla
JOHANNESBURG, May 15 - Cipla Medpro South Africa said on Wednesday its shareholders had approved a $500 million buyout offer from India's Cipla Ltd.
Cipla launches etanercept biosimilar
MUMBAI - Drugmaker Cipla Ltd said on Wednesday it has launched etanercept biosimilar in India under the brand name Etacept.
India's Cipla launches etanercept biosimilar
MUMBAI, April 17 - Indian drugmaker Cipla Ltd said on Wednesday it has launched etanercept biosimilar in India under the brand name Etacept.
Natco, Cipla gain after Supreme Court dismisses Novartis petition
Reuters Market Eye - Shares in Natco Pharma and Cipla gain after the Supreme Court dismissed Swiss drugmaker Novartis AG's petition seeking patent for its cancer drug Glivec.
MARKET EYE-Natco, Cipla up; India's top court dismisses Novartis petition
* Shares in Natco Pharma Ltd and Cipla Ltd gain after India's highest court dismissed Swiss drugmaker Novartis AG's petition seeking patent for its cancer drug Glivec. * In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law. * Analysts say that will be a big win for generic drugmakers given huge difference in prices of monopoly drugs, and as
Top Medpro shareholder says Cipla should raise offer
JOHANNESBURG - A top shareholder in Cipla Medpro said on Tuesday it would ask India's Cipla Ltd to raise its $500 million offer for South Africa's third-largest generic drugs firm.
India's Cipla should pay more for Medpro, says top shareholder
JOHANNESBURG, March 12 - A top shareholder in Cipla Medpro said on Tuesday it would ask India's Cipla Ltd to raise its $500 million offer for South Africa's third-largest generic drugs firm.
Cipla bids $500 million for South Africa affiliate
MUMBAI/JOHANNESBURG - Indian drugmaker Cipla Ltd offered over $500 million to buy out South African affiliate Cipla Medpro on Thursday, sweetening its bid by 17 percent after earlier talks stalled over price.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
